Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I TrialMasoud Solaymani Dodaran,Seyed Reza Banihashemi,Ali Es-haghi,Mohammad Hossein Fallah Mehrabadi,Mojtaba Nofeli,Ali Rezaei Mokarram,Ladan Mokhberalsafa,Fariba Sadeghi,Alireza Ranjbar,Akram Ansarifar,Arash Mohazzab,Seyed Amin Setarehdan,Fahimeh Bagheri Amiri,Vahideh Mohseni,Monireh Hajimoradi,Neda Ghahremanzadeh, Seyed Hossein Razzaz, Safdar Masoomi,Maryam Taghdiri,Mohsen Bagheri,Mohsen Lofti,Akbar Khorasani,Masoud Ghader,Shiva Safari,Masumeh Shahsavn,Saeed KalantariVACCINES（2023）引用 3|浏览15暂无评分关键词SARS-CoV-2,recombinant vaccine,immune response,immunogenicity,intranasal vaccineAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
